MedTrace Logo

Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer

NCT02324088 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2021-02-21

No results posted yet for this study

Summary

To evaluate the benefit of adding docetaxel-5 fluorouracile (D-5FU) regimen after pre-operative epirubicin-cyclophosphamide (EC) and loco-regional treatment in inflammatory breast cancer (IBC).

Conditions

  • Inflammatory Breast Cancer

Interventions

DRUG

Docetaxel

DRUG

Cyclophosphamide

DRUG

Epirubicin

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Patrice Viens, MD · Institut Paoli Calmette Marseille

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2012-12-31
Completion
2015-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02324088 on ClinicalTrials.gov